Search - tctmd.com

Displaying 41 - 52 of 52

Sort: Relevancy | Date

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

News Conference News AHA 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

November 15, 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

News Conference News AHA 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Michael O'Riordan

November 13, 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presentation AHA 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presenter: Akihiko Nogami

November 13, 2017

News Conference News AHA 2016

误诊 NOAC 在日常实践中很常见，并对中风和出血有影响

November 21, 2016

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

November 21, 2016

News Conference News AHA 2016

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

November 21, 2016

News Conference News AHA 2016

亚临床型房颤常见于老年无症状患者

November 18, 2016

News Conference News AHA 2016

Subclinical A-fib Common in Older, Asymptomatic Patients

November 18, 2016

News Conference News AHA 2016

La FA Subclínica es Común en Pacientes Asintomáticos de Mayor Edad

November 18, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.